Your browser doesn't support javascript.
Outcomes of head and neck cancer management from two cancer centres in Southern and Northern Europe during the first wave of COVID-19.
Tagliabue, Marta; Russell, Beth; Moss, Charlotte; De Berardinis, Rita; Chu, Francesco; Jeannon, Jean-Pierre; Pietrobon, Giacomo; Haire, Anna; Grosso, Enrica; Wylie, Harriet; Zorzi, Stefano; Proh, Michele; Brunet-Garcia, Aina; Cattaneo, Augusto; Oakley, Richard; De Benedetto, Luigi; Arora, Asit; Riccio, Stefano; Fry, Alistair; Bruschini, Roberto; Townley, William; Giugliano, Gioacchino; Orfaniotis, Georgios; Madini, Marzia; Dolly, Saoirse; Borghi, Ester; Aprile, Danila; Zurlo, Valeria; Bibiano, Debora; Mastrilli, Fabrizio; Chiocca, Susanna; Van Hemelrijck, Mieke; Gandini, Sara; Simo, Ricard; Ansarin, Mohssen.
  • Tagliabue M; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
  • Russell B; Department of Biomedical Sciences, University of Sassari, Sassari, Italy.
  • Moss C; Faculty of Life Sciences and Medicine, Translational Oncology & Urology Research (TOUR), King's College London, London, UK.
  • De Berardinis R; Faculty of Life Sciences and Medicine, Translational Oncology & Urology Research (TOUR), King's College London, London, UK.
  • Chu F; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
  • Jeannon JP; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
  • Pietrobon G; Head, Neck and Thyroid Oncology Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK.
  • Haire A; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
  • Grosso E; Faculty of Life Sciences and Medicine, Translational Oncology & Urology Research (TOUR), King's College London, London, UK.
  • Wylie H; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
  • Zorzi S; Faculty of Life Sciences and Medicine, Translational Oncology & Urology Research (TOUR), King's College London, London, UK.
  • Proh M; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
  • Brunet-Garcia A; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
  • Cattaneo A; Head, Neck and Thyroid Oncology Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK.
  • Oakley R; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
  • De Benedetto L; Head, Neck and Thyroid Oncology Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK.
  • Arora A; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
  • Riccio S; Head, Neck and Thyroid Oncology Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK.
  • Fry A; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
  • Bruschini R; Head, Neck and Thyroid Oncology Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK.
  • Townley W; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
  • Giugliano G; Head, Neck and Thyroid Oncology Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK.
  • Orfaniotis G; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
  • Madini M; Head, Neck and Thyroid Oncology Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK.
  • Dolly S; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
  • Borghi E; Department of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Aprile D; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
  • Zurlo V; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
  • Bibiano D; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
  • Mastrilli F; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
  • Chiocca S; Medical Administration, CMO, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
  • Van Hemelrijck M; Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.
  • Gandini S; Faculty of Life Sciences and Medicine, Translational Oncology & Urology Research (TOUR), King's College London, London, UK.
  • Simo R; Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.
  • Ansarin M; Head, Neck and Thyroid Oncology Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK.
Tumori ; 108(3): 230-239, 2022 Jun.
Article in English | MEDLINE | ID: covidwho-1181055
ABSTRACT

OBJECTIVE:

To describe the approach and outcomes from two cancer centres in Southern and Northern Europe during the first wave of coronavirus disease 2019 (COVID-19) of patients with head and neck cancer (HNC).

METHODS:

Data collection was performed on a retrospective cohort of patients surgically treated for primary HNC between March and May 2020, using data from two tertiary hospitals the European Institute of Oncology (Milan) and Guy's & St Thomas' NHS Foundation Trust (London).

RESULTS:

We included 77 patients with HNC. More patients with COVID-19 were taking angiotensin-converting enzyme (ACE) inhibitors and had Clavien-Dindo Classification grade I compared to negative patients, respectively (60% vs 22% [p = 0.058] and 40% vs 8% [p = 0.025]). Multivariate logistic regression analyses confirmed our data (p = 0.05 and 0.03, respectively). Sex and age were statistically significantly different (p = 0.05 and <0.001 respectively), showing more male patients (75% vs 53.66%, respectively) and more elderly patients in Italy than in the United Kingdom (patients aged >63 years 69.44% vs 29.27%).

CONCLUSIONS:

This study presents a large cohort of patients with HNC with nasopharyngeal swab during the first peak of the COVID-19 pandemic in Europe. Patients with HNC with COVID-19 appeared more likely to develop postsurgical complications and to be taking ACE inhibitors. The preventive measures adopted guaranteed the continuation of therapeutic surgical intervention.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Head and Neck Neoplasms Type of study: Cohort study / Observational study / Prognostic study Limits: Aged / Humans / Male Country/Region as subject: Europa Language: English Journal: Tumori Year: 2022 Document Type: Article Affiliation country: 03008916211007927

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Head and Neck Neoplasms Type of study: Cohort study / Observational study / Prognostic study Limits: Aged / Humans / Male Country/Region as subject: Europa Language: English Journal: Tumori Year: 2022 Document Type: Article Affiliation country: 03008916211007927